Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) Short Interest Down 10.4% in December

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) (TSE:CPH) saw a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 116,700 shares, a drop of 10.4% from the December 15th total of 130,300 shares. Based on an average daily volume of 22,700 shares, the short-interest ratio is presently 5.1 days.

Cipher Pharmaceuticals Price Performance

Shares of Cipher Pharmaceuticals stock traded up $0.37 on Friday, reaching $9.72. The stock had a trading volume of 22,888 shares, compared to its average volume of 19,199. The business’s 50-day moving average price is $10.17 and its two-hundred day moving average price is $10.29. Cipher Pharmaceuticals has a fifty-two week low of $4.14 and a fifty-two week high of $14.60.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.